<DOC>
	<DOC>NCT01166620</DOC>
	<brief_summary>To quantify the incremental cost of infections in patients treated with etanercept, adalimumab or infliximab versus abatacept.</brief_summary>
	<brief_title>Observational Real-world Evaluation of Cost of Infections of Rheumatoid Arthritis (RA) Patients on Biologics</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>18 years of age and older; Have a diagnosis of of rheumatoid arthritis (ICD9:714x.xx); Have been enrolled for at least 6 months for the 6 months assessment and 12 months for the 12 months assessment; are enrolled in a health plan between February 2006 and June 2009 have claims indicating at least one use of either abatacept, etanercept, adalimumab or infliximab for at least 6 months for teh 6 months assessment and 12 months for the 12 months assessment Patients not continuously eligible for health plan benefits for the same evaluation periods will be excluded Patients who are on other biologics in the 6 and 12 month postindex period will be excluded (ex. those in the abatacept cohort will be excluded if they also have claims for etanercept in the 6 and 12 month postindex period). Patients on biologics 6 months prior to the biologic index date will also be excluded Patients with diagnosis for other nonRA conditions commonly treated with biologics (ex. Crohn's disease) during the 6 month preindex period.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>